Crossject Société Anonyme (FRA:74C)

Market Cap	88.74M +5.2%
Revenue (ttm)	2.57M -37.6%
Net Income	-10.37M
EPS	-0.20
Shares Out	n/a
PE Ratio	n/a
Forward PE	3.14
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Open	1.500
Previous Close	1.510
Day's Range	1.500 - 1.500
52-Week Range	1.380 - 2.590
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Sep 23, 2026

About Crossject Société Anonyme

Crossject Société Anonyme develops needle-free injection systems in France. The company develops ZENEO, needle-free, pre-filled, single-use auto-injector. It offers Midazolam for epileptic seizure; Terbutaline for the treatment of severe asthma crisis; Epinephrine for anaphylactic shock; and Sumatriptan for the treatment of migraine and cluster headaches, as well as Hydrocortisone for acute adrenal crisis and Methotrexate for the treatment of rheumatoid arthritis. In addition, the company is developing ZEPIZURE, an emergency treatment for manag...

• Industry: Surgical and Medical Instruments and Apparatus
• Founded: 2001
• Employees: 99
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 74C

Financial Performance

In 2025, Crossject Société Anonyme's revenue was 2.57 million, a decrease of -37.59% compared to the previous year's 4.12 million. Losses were -10.37 million, -18.97% less than in 2024.

Data Sources: S&P Global Market Intelligence and Twelve Data

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Twelve Data.

Last checked:

Jul 20, 2026

Data Sources Report a data error